282 related articles for article (PubMed ID: 32229495)
21. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study.
Hulhoven R; Rosillon D; Letiexhe M; Meeus MA; Daoust A; Stockis A
Eur J Clin Pharmacol; 2007 Nov; 63(11):1011-7. PubMed ID: 17891537
[TBL] [Abstract][Full Text] [Related]
22. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
[TBL] [Abstract][Full Text] [Related]
23. Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.
Wang Z; Xuan F; Lin WH; Troyer MD; Tendolkar A; Cutler DL
Eur J Clin Pharmacol; 2013 Oct; 69(10):1761-7. PubMed ID: 23857248
[TBL] [Abstract][Full Text] [Related]
24. Effects of Nemonoxacin on Thorough ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled Crossover Study in Healthy Chinese Adults.
Zhao C; Lv Y; Li X; Hou F; Ma X; Wei M; Kang Z; Cui L; Xia Y; Liu Y; Tian J
Clin Ther; 2018 Jun; 40(6):983-992. PubMed ID: 29803534
[TBL] [Abstract][Full Text] [Related]
25. Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects.
Täubel J; Ferber G; Fox G; Fernandes S; Lorch U; Camm AJ
Br J Clin Pharmacol; 2017 Feb; 83(2):339-348. PubMed ID: 27618796
[TBL] [Abstract][Full Text] [Related]
26. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
Stier B; Fossler M; Liu F; Caltabiano S
Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
[TBL] [Abstract][Full Text] [Related]
27. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
Ring A; Brand T; Macha S; Breithaupt-Groegler K; Simons G; Walter B; Woerle HJ; Broedl UC
Cardiovasc Diabetol; 2013 Apr; 12():70. PubMed ID: 23617452
[TBL] [Abstract][Full Text] [Related]
28. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
Iyer GR; Darpo B; Xue H; Lecot J; Zack J; Bebrevska L; Weis W; Jones I; Drollmann A
Clin Pharmacol Drug Dev; 2024 May; 13(5):572-584. PubMed ID: 38284433
[TBL] [Abstract][Full Text] [Related]
29. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
Schilling U; Henrich A; Muehlan C; Krause A; Dingemanse J; Ufer M
Clin Drug Investig; 2021 Aug; 41(8):711-721. PubMed ID: 34331678
[TBL] [Abstract][Full Text] [Related]
30. Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers.
Taubel J; Naseem A; Wang D; Arezina R; Lorch U; Camm AJ
Br J Clin Pharmacol; 2012 Aug; 74(2):296-303. PubMed ID: 22283848
[TBL] [Abstract][Full Text] [Related]
31. Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval.
Donegan DM; Pivonello R; Stigliano A; Lardo P; Kearney T; Mezősi E; Ghigo E; Giordano R; Mariash CN; Feelders RA; Donaldson K; Darpo B; Xue H; Custodio JM; Hand AL; Moraitis AG
Endocr Pract; 2024 Jan; 30(1):11-18. PubMed ID: 37805100
[TBL] [Abstract][Full Text] [Related]
32. Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men.
Olsson H; Petri N; Erichsen L; Malmberg A; Grundemar L
Clin Drug Investig; 2017 Sep; 37(9):873-879. PubMed ID: 28660498
[TBL] [Abstract][Full Text] [Related]
33. Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: A randomized, placebo- and positive-controlled thorough QT study in healthy individuals.
Prince WT; Venishetty VK; Lecot J; Shakeri-Nejad K; Gray C; Taylor A; Iyer GR; Zack J
Clin Transl Sci; 2023 Oct; 16(10):1758-1767. PubMed ID: 37688315
[TBL] [Abstract][Full Text] [Related]
34. Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study.
Shah RR; Maison-Blanche P; Duvauchelle T; Robert P; Denis E
Eur J Clin Pharmacol; 2015 Dec; 71(12):1451-9. PubMed ID: 26423621
[TBL] [Abstract][Full Text] [Related]
35. Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.
Timmers M; Sinha V; Darpo B; Smith B; Brown R; Xue H; Ferber G; Streffer J; Russu A; Tritsmans L; Solanki B; Bogert J; Van Nueten L; Salvadore G; Nandy P
J Clin Pharmacol; 2018 Jul; 58(7):952-964. PubMed ID: 29505101
[TBL] [Abstract][Full Text] [Related]
36. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Kubitza D; Mueck W; Becka M
Drug Saf; 2008; 31(1):67-77. PubMed ID: 18095747
[TBL] [Abstract][Full Text] [Related]
39. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.
Dubourg J; Perrimond-Dauchy S; Felices M; Bolze S; Voiriot P; Fouqueray P
Eur J Clin Pharmacol; 2020 Oct; 76(10):1393-1400. PubMed ID: 32556539
[TBL] [Abstract][Full Text] [Related]
40. Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate.
Liang LY; He YC; Li YF; Yang J; Xu FY; Li LJ; Huang JH; Wang K; Zheng QS
Biomed Pharmacother; 2020 Oct; 130():110619. PubMed ID: 32795925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
